Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.
तुलना करने के लिए मीट्रिक्स | 6634 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध6634पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −19.2x | −7.0x | −0.5x | |
PEG अनुपात | −0.93 | 0.04 | 0.00 | |
क़ीमत/बुक | 2.4x | 1.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 3.0x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 91.3% | 45.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | −3.7% | 5.7% | अनलॉक करें |